Allergy Towards Grass and Bronchial Inflammation - Related to Immunotherapy and Exhaled Nitrogen Oxide

The recruitment status of this study is unknown because the information has not been verified recently.

Verified September 2006 by Bispebjerg Hospital. Recruitment status was Recruiting

First Received on April 5, 2006. Last Updated on June 11, 2007 History of Changes

Sponsor:	Bispebjerg Hospital
Information provided by:	Bispebjerg Hospital
ClinicalTrials.gov Identifier:	NCT00312312

Purpose

The purpose of this study is to evaluate the immunomodulatory effect of treatment of allergic rhinitis symptoms with specific immunotherapy by measurement of pulmonary inflammatory markers, and among others, exhaled nitric oxide.

Condition	Intervention
Asthma, Bronchial Allergic Rhinitis Hypersensitivity, Immediate	Biological: Specific immunotherapy

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention
Official Title:	Does Specific Immunotherapy Possess Immunomodulative Effects at the Bronchial Mucosa Level Among Adults With Atopic Diseases?

Resource links provided by NLM:

MedlinePlus related topics: Allergy Asthma

U.S. FDA Resources

Further study details as provided by Bispebjerg Hospital:

Primary Outcome Measures:

Skin prick test
Spirometry
Methacholine provocation of the pulmonary system
Exhaled nitric oxide
Immunoglobulin E (IgE) status
Sputum examination
Condensation of exhaled air

Secondary Outcome Measures:

Questionnaire

Estimated Enrollment:	40
Study Start Date:	March 2006
Estimated Study Completion Date:	December 2008

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age 18-45 years old
Skin prick test or RAS test and physical examination conclude that the patient will have a beneficial effect from specific immunotherapy

Exclusion Criteria:

Other diseases except atopic disease
Pregnancy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00312312

Contacts

Contact: Thomas B Knudsen, Medical student	+45 61 70 96 99	thomas@uknet.dk
Contact: Vibeke Backer, M.D., M.D.Sci	+45 35 31 30 69	backer@dadlnet.dk

Locations

Denmark
Bispebjerg Hospital	Recruiting
Copenhagen, Denmark, 2400 NV
Contact: Thomas B Knudsen, Medical student +45 61 70 96 99 thomas@uknet.dk
Sub-Investigator: Thomas B Knudsen, Medical student

Sponsors and Collaborators

Bispebjerg Hospital

Investigators

Principal Investigator:

Vibeke Backer, M.D., M.D.Sci

Lungeforskningsenheden v/Bispebjerg hospital

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00312312 History of Changes
Other Study ID Numbers:	SITNO
Study First Received:	April 5, 2006
Last Updated:	June 11, 2007
Health Authority:	Denmark: The Regional Committee on Biomedical Research Ethics

Keywords provided by Bispebjerg Hospital:

Asthma
Allergic rhinitis
Atopy

Exhaled nitric oxide
Specific immunotherapy
Atopic diseases

Additional relevant MeSH terms:

Asthma
Hypersensitivity
Hypersensitivity, Immediate
Rhinitis
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive

Lung Diseases
Respiratory Hypersensitivity
Immune System Diseases
Nose Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases

ClinicalTrials.gov processed this record on February 12, 2012